Telix Pharmaceuticals Valuation
| TLPPF Stock | USD 16.00 0.82 5.40% |
At this time, the company appears to be overvalued. Telix Pharmaceuticals has a current Real Value of $12.88 per share. The regular price of the company is $16.0. Our model measures the value of Telix Pharmaceuticals from inspecting the company fundamentals such as Return On Equity of -1.55, current valuation of 1.39 B, and Shares Owned By Insiders of 27.60 % as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Telix Pharmaceuticals' price fluctuation is somewhat reliable at this time. Calculation of the real value of Telix Pharmaceuticals is based on 3 months time horizon. Increasing Telix Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Telix pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Telix Pharmaceuticals Limited. Since Telix Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Telix Pink Sheet. However, Telix Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 16.0 | Real 12.88 | Hype 16.0 | Naive 16.19 |
The real value of Telix Pink Sheet, also known as its intrinsic value, is the underlying worth of Telix Pharmaceuticals Company, which is reflected in its stock price. It is based on Telix Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Telix Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Telix Pharmaceuticals Limited helps investors to forecast how Telix pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Telix Pharmaceuticals more accurately as focusing exclusively on Telix Pharmaceuticals' fundamentals will not take into account other important factors: Telix Pharmaceuticals Total Value Analysis
Telix Pharmaceuticals Limited is at this time projected to have takeover price of 1.39 B with market capitalization of 1.44 B, debt of 2.57 M, and cash on hands of 122.61 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Telix Pharmaceuticals fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.39 B | 1.44 B | 2.57 M | 122.61 M |
Telix Pharmaceuticals Investor Information
About 28.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.2. Telix Pharmaceuticals had not issued any dividends in recent years. Based on the key indicators related to Telix Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Telix Pharmaceuticals Limited is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.Telix Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Telix Pharmaceuticals has an asset utilization ratio of 4.46 percent. This implies that the Company is making $0.0446 for each dollar of assets. An increasing asset utilization means that Telix Pharmaceuticals Limited is more efficient with each dollar of assets it utilizes for everyday operations.Telix Pharmaceuticals Ownership Allocation
Telix Pharmaceuticals shows a total of 317.02 Million outstanding shares. Telix Pharmaceuticals maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Telix Pharmaceuticals Profitability Analysis
The company reported the revenue of 4.9 M. Net Loss for the year was (80.51 M) with profit before overhead, payroll, taxes, and interest of 5.05 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Telix Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Telix Pharmaceuticals and how it compares across the competition.
About Telix Pharmaceuticals Valuation
The pink sheet valuation mechanism determines Telix Pharmaceuticals' current worth on a weekly basis. Our valuation model uses a comparative analysis of Telix Pharmaceuticals. We calculate exposure to Telix Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Telix Pharmaceuticals's related companies.Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company was founded in 2015 and is headquartered in North Melbourne, Australia. Telix Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange.
8 Steps to conduct Telix Pharmaceuticals' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Telix Pharmaceuticals' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Telix Pharmaceuticals' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Telix Pharmaceuticals' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Telix Pharmaceuticals' revenue streams: Identify Telix Pharmaceuticals' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Telix Pharmaceuticals' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Telix Pharmaceuticals' growth potential: Evaluate Telix Pharmaceuticals' management, business model, and growth potential.
- Determine Telix Pharmaceuticals' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Telix Pharmaceuticals' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Telix Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Telix Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 285.1 M | |
| Forward Price Earnings | 21.5517 | |
| Retained Earnings | -173.5 M |
Complementary Tools for Telix Pink Sheet analysis
When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |